Skip to main content

Table 4 Overall mortality rate by disease and treatment received

From: COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  Overall mortality
  Survived n (%) Died n (%)
Baseline hematological malignancies
Acute lymphoid leukemia 125 (74) 44 (26)
Chronic lymphoid leukemia 340 (71.7) 134 (28.3)
Acute myeloid leukemia 298 (60) 199 (40)
Chronic myeloid leukemia 144 (89.5) 17 (10.5)
Myelodysplastic syndrome 161 (57.7) 118 (42.3)
 Low-intermediate risk 77 (55.8) 61 (44.2)
 High risk 26 (54.2) 22 (45.8)
 Not stated 58 (62.4) 35 (37.6)
Hairy cell leukemia 15 (65.2) 8 (34.8)
Hodgkin lymphoma 120 (88.9) 15 (11.1)
Non-Hodgkin lymphoma 739 (68.2) 345 (31.8)
 Indolent 354 (71.3) 143 (28.7)
 Aggressive 337 (65.3) 179 (34.7)
 Not stated 48 (67.6) 23 (32.4)
Essential thrombocythemia 57 (82.6) 12 (17.4)
Myelofibrosis 77 (63.1) 45 (36.9)
Polycythemia vera 56 (80) 14 (20)
Systemic mastocytosis 5 (83.4) 1 (16.6)
Multiple Myeloma 458 (67) 226 (33)
Amyloidosis 7 (87.5) 1 (12.5)
Aplastic anemia 14 (70) 6 (30)
Last/ongoing treatment strategy before COVID-19
Anagrelide/Hydroxyurea 106 (73.1) 39 (26.9)
Conventional chemotherapy 423 (70.9) 174 (29.1)
Hypomethylating agents 58 (41.2) 83 (58.8)
Immunotherapy only 89 (71.2) 36 (28.8)
Immunochemotherapy 595 (69.4) 262 (30.6)
Immunomodulators 139 (63.8) 79 (36.2)
Targeted therapya 453 (74.6) 154 (25.4)
Allogeneic HSCT 130 (75.2) 43 (24.8)
Autologous HSCT 54 (73) 20 (27)
CAR-T 11 (52.4) 10 (47.6)
Radiotherapy 9 (90) 1 (10)
Palliative/supportive measures 122 (56) 104 (46)
Other 17 (60.7) 11 (39.3)
Unknown 28 (68.3) 13 (31.7)
No treatment 382 (71) 156 (29)
  1. HSCT Hematopoietic stem cell transplantation, CAR-T chimeric antigen receptor T-cell therapies
  2. aBortezomib, ibrutinib, idelalisib, ruxolitinib, TKI (tyrosine kinase inhibitors) and venetoclax